ANIP ANI PHARMACEUTICALS INC
FY2025 10-K
ANI PHARMACEUTICALS INC (ANIP) filed its fiscal year 2025 10-K annual report with the SEC on Feb 27, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: developing, manufacturing, commercializing therapeutics via Rare Disease, Generics, and Brands segments
- • Acquired Alimera Sciences on September 16, 2024, adding ILUVIEN® and YUTIQ® products
Management Discussion & Analysis
- • Total revenue details not provided for FY 2024; Alimera acquisition adds ILUVIEN® and YUTIQ® franchises
- • No specific operating margin or profitability figures mentioned in the available excerpt
Risk Factors
- • Regulatory/legal risk: Compliance with Medicaid Drug Rebate Program risks material penalties due to increased rebate accruals from branded and authorized generic products
- • Geopolitical/macro risk: 17% of raw materials/API from one domestic supplier in 2025; supply disruption risk from FDA inspections and trade or geopolitical tensions
Get deeper insights on ANI PHARMACEUTICALS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.